BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 24752781)

  • 1. No small surprise - small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour.
    Foulkes WD; Clarke BA; Hasselblatt M; Majewski J; Albrecht S; McCluggage WG
    J Pathol; 2014 Jul; 233(3):209-14. PubMed ID: 24752781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor.
    Fahiminiya S; Witkowski L; Nadaf J; Carrot-Zhang J; Goudie C; Hasselblatt M; Johann P; Kool M; Lee RS; Gayden T; Roberts CW; Biegel JA; Jabado N; Majewski J; Foulkes WD
    Oncotarget; 2016 Jan; 7(2):1732-40. PubMed ID: 26646792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
    Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
    J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcaemic type.
    Errichiello E; Mustafa N; Vetro A; Notarangelo LD; de Jonge H; Rinaldi B; Vergani D; Giglio SR; Morbini P; Zuffardi O
    J Pathol; 2017 Sep; 243(1):9-15. PubMed ID: 28608987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-Cell Carcinoma of the Ovary of Hypercalcemic Type (Malignant Rhabdoid Tumor of the Ovary): A Review with Recent Developments on Pathogenesis.
    Witkowski L; Goudie C; Foulkes WD; McCluggage WG
    Surg Pathol Clin; 2016 Jun; 9(2):215-26. PubMed ID: 27241105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas.
    Karanian-Philippe M; Velasco V; Longy M; Floquet A; Arnould L; Coindre JM; Le Naoures-Méar C; Averous G; Guyon F; MacGrogan G; Croce S
    Am J Surg Pathol; 2015 Sep; 39(9):1197-205. PubMed ID: 26135561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMARCA4-deficient rhabdoid tumours show intermediate molecular features between SMARCB1-deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type.
    Andrianteranagna M; Cyrta J; Masliah-Planchon J; Nemes K; Corsia A; Leruste A; Holdhof D; Kordes U; Orbach D; Corradini N; Entz-Werle N; Pierron G; Castex MP; Brouchet A; Weingertner N; Ranchère D; Fréneaux P; Delattre O; Bush J; Leary A; Frühwald MC; Schüller U; Servant N; Bourdeaut F
    J Pathol; 2021 Sep; 255(1):1-15. PubMed ID: 33999421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SMARCA4-deficient undifferentiated carcinoma of the ovary (small cell carcinoma, hypercalcemic type): clinicopathologic and immunohistochemical study of 3 cases.
    Agaimy A; Thiel F; Hartmann A; Fukunaga M
    Ann Diagn Pathol; 2015 Oct; 19(5):283-7. PubMed ID: 26123103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Report of a Bilateral Case in a Teenager Associated with SMARCA4 Germline Mutation.
    Lavrut PM; Le Loarer F; Normand C; Grosos C; Dubois R; Buenerd A; Conter C; Dijoud F; Blay JY; Collardeau-Frachon S
    Pediatr Dev Pathol; 2016; 19(1):56-60. PubMed ID: 26230154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial rhabdoid tumour 'avant la lettre'--from pathology review to exome sequencing and back again.
    Witkowski L; Lalonde E; Zhang J; Albrecht S; Hamel N; Cavallone L; May ST; Nicholson JC; Coleman N; Murray MJ; Tauber PF; Huntsman DG; Schönberger S; Yandell D; Hasselblatt M; Tischkowitz MD; Majewski J; Foulkes WD
    J Pathol; 2013 Sep; 231(1):35-43. PubMed ID: 23775540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases.
    Witkowski L; Donini N; Byler-Dann R; Knost JA; Albrecht S; Berchuck A; McCluggage WG; Hasselblatt M; Foulkes WD
    Fam Cancer; 2017 Jul; 16(3):395-399. PubMed ID: 27866340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
    Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
    Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biallelic somatic SMARCA4 mutations in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
    Bailey S; Murray MJ; Witkowski L; Hook E; Hasselblatt M; Crawford R; Foulkes WD; Tischkowitz M; Nicholson JC
    Pediatr Blood Cancer; 2015 Apr; 62(4):728-30. PubMed ID: 25307865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics.
    Clarke BA; Witkowski L; Ton Nu TN; Shaw PA; Gilks CB; Huntsman D; Karnezis AN; Sebire N; Lamovec J; Roth LM; Stewart CJ; Hasselblatt M; Foulkes WD; McCluggage WG
    Histopathology; 2016 Nov; 69(5):727-738. PubMed ID: 27100627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology.
    Ramalingam P; Croce S; McCluggage WG
    Histopathology; 2017 Feb; 70(3):359-366. PubMed ID: 27656868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.
    Holdhof D; Johann PD; Spohn M; Bockmayr M; Safaei S; Joshi P; Masliah-Planchon J; Ho B; Andrianteranagna M; Bourdeaut F; Huang A; Kool M; Upadhyaya SA; Bendel AE; Indenbirken D; Foulkes WD; Bush JW; Creytens D; Kordes U; Frühwald MC; Hasselblatt M; Schüller U
    Acta Neuropathol; 2021 Feb; 141(2):291-301. PubMed ID: 33331994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathological and molecular features of malignancies underlined by BAF complexes inactivation].
    Le Quang M; Ranchère-Vince D; Le Loarer F
    Ann Pathol; 2019 Dec; 39(6):399-413. PubMed ID: 31255411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
    Lin DI; Chudnovsky Y; Duggan B; Zajchowski D; Greenbowe J; Ross JS; Gay LM; Ali SM; Elvin JA
    Gynecol Oncol; 2017 Dec; 147(3):626-633. PubMed ID: 29102090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression.
    Hasselblatt M; Gesk S; Oyen F; Rossi S; Viscardi E; Giangaspero F; Giannini C; Judkins AR; Frühwald MC; Obser T; Schneppenheim R; Siebert R; Paulus W
    Am J Surg Pathol; 2011 Jun; 35(6):933-5. PubMed ID: 21566516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond
    Auguste A; Blanc-Durand F; Deloger M; Le Formal A; Bareja R; Wilkes DC; Richon C; Brunn B; Caron O; Devouassoux-Shisheboran M; Gouy S; Morice P; Bentivegna E; Sboner A; Elemento O; Rubin MA; Pautier P; Genestie C; Cyrta J; Leary A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32575483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.